Respiratory News and Research

RSS

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer Inc. announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline.

5 May 2012

Scanning the evidence for evidence in RTIs: NPS webinar

Next week NPS will host its inaugural webinar for GPs looking at medical imaging in respiratory tract infections (RTIs). Forming part of the NPS campaign on antibiotic resistance, the webinar on 10 May enables GPs to engage with imaging experts in real-time and gain insights into when imaging is appropriate for RTIs.

4 May 2012

One of the controversial avian flu studies published in full finally

After endless debates and controversies on whether two studies that demonstrated how bird flu, also known as avian H5N1 influenza, or avian flu, should be published, one of them has appeared in the latest issue of the journal Nature in its entirety. The two studies aimed for publication in journals Nature and Science show how the bird flu virus could become transmissible from mammal-to-mammal; as humans are mammals, the same would apply to humans.

4 May 2012

U of A engineers develop wireless health-monitoring system

An interdisciplinary team of engineers at the University of Arkansas has developed a wireless health-monitoring system that gathers critical patient information, regardless of the patient's location, and communicates that information in real time to a physician, hospital or the patient herself.

4 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Clinical trial to investigate statins in patients with acute severe respiratory failure

Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.

4 May 2012

MediServe launches Attigo Therapy

Rehabilitation software solution specialist MediServe is expanding its product line, launching a new all-in-one Web-based software solution designed specifically to help private practice therapy providers increase their profits.

4 May 2012

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

4 May 2012

Comorbidities common among patients with COPD

Comorbidities are common among patients with chronic obstructive pulmonary disease (COPD), and a number of these comorbidities are independently associated with an increased mortality risk, according to a new study.

4 May 2012

15 million preterm babies born each year: WHO global report

According to a new report released this Wednesday, nearly 15 million premature babies are born every year - more than 1 in 10 of the world's births. This is considered by experts an obstetric epidemic. 1.1 million of these fragile new born babies die as a result, and even those who survive can suffer lifelong disabilities. Further most of these babies are born in Africa and Asia the report adds.

3 May 2012

Prematurity now the second-leading cause of death worldwide in children under age 5

The first-ever national, regional, and global estimates of preterm birth reveals that 15 million babies are born too soon every year and 1.1 million of those babies die shortly after birth, making premature birth the second-leading cause of death in children under age 5.

3 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Diagnosis of neonatal abstinence syndrome triples between 2000 and 2009

About one baby is born every hour addicted to opiate drugs in the United States, according to new research from University of Michigan physicians.

2 May 2012

Teleflex launches Hudson RCI Softech Plus to help clinicians

Teleflex Incorporated has announced the introduction of Hudson RCI Softech Plus, a line of oxygen cannulas designed to help clinicians improve patient comfort and reduce DEHP exposure.

2 May 2012

Teleflex strengthens Anesthesia product portfolio

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired the EZ-BlockerTM disposable catheter product line with a unique bifurcated distal end, a novel and patented bronchial blocker for lung isolation and one-lung ventilation.

2 May 2012

'Taboo' surrounding toilets, sanitation hindering progress toward improved access

"Governments are failing to fund projects to improve access to toilets and other sanitation services in poor countries because the subject remains 'taboo,' a director at the Bill & Melinda Gates Foundation said on Monday," Reuters reports. "About 1.1 billion people across the world still defecate in the open because they have no toilets, according to the United Nations," Reuters writes.

2 May 2012

Covidien acquires Newport Medical

Covidien plc, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that it has completed the previously announced acquisition of Newport Medical Instruments, Inc. for an aggregate consideration of approximately $108 million, net of cash and short-term investments acquired.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

Only few clinical trials are being conducted to test drugs in pediatric patients

Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study to be presented Saturday, April 28, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012